Industry Partner News: Catabasis Reports Positive Efficacy Results in Quarterly Newsletter

Please see the Catabasis Quarterly Newsletter to learn about the new positive efficacy results were reported following 24 and 36 weeks of treatment with 100 mg/kg/day oral edasalonexent in the MoveDMD Phase 2 trial open-label extension, and plans to start a Phase 3 trial of edasalonexent in patients affected by Duchenne the first half of 2018.